Individuals with pathogenic variants affecting biologically relevant CDKN2A isoforms (i.e., p16INK4A and p14ARF) are recommended for surveillance for both melanoma and pancreatic cancer [11, 12]. This evidence concerns the gene CDKN2A and melanoma.